NBC News

Infinity Announces Promising Phase 1 Data of IPI-926 in Patients With Advanced or Metastatic Solid Tumors

Oct. 10, 2010, 10:45 AM UTC / Source: GlobeNewswire MILAN, Italy, Oct. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced promising preliminary results from a ...
Nasdaq

Infinity Focuses on Developing IPI-549 for Solid Tumors

We issued an updated research report on Infinity Pharmaceuticals, Inc. INFI on Aug 21. Infinity is currently focused on the development of its lead candidate, IPI-549. In November 2016, Infinity ...
Business Wire

Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the expansion of its pipeline with the addition of IPI-549, an orally administered immuno-oncology ...
ecoustics

Exceptional By Design: Infinity Introduces Total Solutions Systems With Striking New Striking New Styling And Upgraded Primus Series Loudspeakers at CEDIA 2006

— TSS-1200, TSS-800 and TSS-500 Speaker Systems, Redesigned Primus Series and Award-Winning Cascade Loudspeakers Among Custom-Installation Solutions Featured at CEDIA Exhibit — WOODBURY, NY — At CEDIA ...